When should a time at risk start in efficacy malaria vaccine trials?
Vaccine
.
2017 Jan 5;35(2):201.
doi: 10.1016/j.vaccine.2016.11.019.
Author
Dawit Asmamaw Ejigu
1
Affiliation
1
Assistant Professor of Pharmacology, St Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia. Electronic address:
[email protected]
.
PMID:
28024560
DOI:
10.1016/j.vaccine.2016.11.019
No abstract available
Publication types
Letter
Comment
MeSH terms
Humans
Malaria / prevention & control*
Malaria Vaccines / immunology*
Malaria, Falciparum / immunology
Substances
Malaria Vaccines